CalciMedica's CM5480 shows promise in PAH treatment, cardiac benefits support AKI therapy.

• CalciMedica's CM5480 shows potential as PAH therapy, both as monotherapy and in combination with existing treatments. • CM5480 acts by selectively and potently inhibiting CRAC channels. • Preclinical data supports cardiac benefit for CRAC channel inhibition in acute kidney injury (AKI). • Phase 2 KOURAGE trial for AKI is underway with data expected in 1H 2026. • CM5480 is a potential first-in-class, differentiated therapy for PAH.